Tight Glycemic Control After Pediatric Cardiac Surgery in High-Risk Patient Populations by Agus, Michael S D et al.
University of Pennsylvania
ScholarlyCommons
School of Nursing Departmental Papers School of Nursing
6-3-2014
Tight Glycemic Control After Pediatric Cardiac
Surgery in High-Risk Patient Populations
Michael S D. Agus
Lisa A. Asaro
Garry M. Steil
Jamin Alexander
Melanie Silverman
See next page for additional authors
Follow this and additional works at: http://repository.upenn.edu/nrs
Part of the Pediatric Nursing Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/nrs/14
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Agus, M. D., Asaro, L. A., Steil, G. M., Alexander, J., Silverman, M., Wypij, D., Gaies, M. G., & Curley, M. A. (2014). Tight Glycemic
Control After Pediatric Cardiac Surgery in High-Risk Patient Populations. Circulation, 129 (22), 2297-2304. http://dx.doi.org/
10.1161/CIRCULATIONAHA.113.008124
Tight Glycemic Control After Pediatric Cardiac Surgery in High-Risk
Patient Populations
Abstract
Background—Our previous randomized, clinical trial showed that postoperative tight glycemic control
(TGC) for children undergoing cardiac surgery did not reduce the rate of health care–associated infections
compared with standard care (STD). Heterogeneity of treatment effect may exist within this population.
Methods and Results—We performed a post hoc exploratory analysis of 980 children from birth to 36
months of age at the time of cardiac surgery who were randomized to postoperative TGC or STD in the
intensive care unit. Significant interactions were observed between treatment group and both neonate (age
≤30 days; P=0.03) and intraoperative glucocorticoid exposure (P=0.03) on the risk of infection. The rate and
incidence of infections in subjects ≤60 days old were significantly increased in the TGC compared with the
STD group (rate: 13.5 versus 3.7 infections per 1000 cardiac intensive care unit days, P=0.01; incidence: 13%
versus 4%, P=0.02), whereas infections among those >60 days of age were significantly reduced in the TGC
compared with the STD group (rate: 5.0 versus 14.1 infections per 1000 cardiac intensive care unit days,
P=0.02; incidence: 2% versus 5%, P=0.03); the interaction of treatment group by age subgroup was highly
significant (P=0.001). Multivariable logistic regression controlling for the main effects revealed that previous
cardiac surgery, chromosomal anomaly, and delayed sternal closure were independently associated with
increased risk of infection.
Conclusions—This exploratory analysis demonstrated that TGC may lower the risk of infection in children
>60 days of age at the time of cardiac surgery compared with children receiving STD. Meta-analyses of past
and ongoing clinical trials are necessary to confirm these findings before clinical practice is altered.
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Abstract
Background—Our previous randomized clinical trial showed that post-operative tight glycemic
control (TGC) for children undergoing cardiac surgery did not reduce the rate of healthcare-
associated infections compared to standard care (STD). Heterogeneity of treatment effect may
exist within this population.
Methods and Results—We performed a post-hoc exploratory analysis on 980 children from
birth to 36 months at the time of cardiac surgery who were randomized to post-operative TGC or
STD in the intensive care unit. Significant interactions were observed between treatment group
and both neonate (age ≤30 days, P=0.03) and intraoperative glucocorticoid exposure (P=0.03) on
the risk of infection. The rate and incidence of infections in subjects ≤60 days old were
significantly increased in the TGC group compared to the STD group (rate 13.5 vs. 3.7 infections/
1,000 CICU days, P=0.01; incidence 13% vs. 4%, P=0.02), while infections among those >60
days of age was significantly reduced in TGC compared to STD (rate 5.0 vs. 14.1 infections/1,000
CICU days, P=0.02; incidence 2% vs. 5%, P=0.03); the treatment group by age subgroup
interaction was highly significant (P=0.001). Multivariable logistic regression controlling for the
main effects revealed that previous cardiac surgery, chromosomal anomaly, and delayed sternal
closure were independently associated with increased risk of infection.
Conclusions—This exploratory analysis demonstrated that TGC may lower the risk of infection
in children >60 days old at the time of cardiac surgery compared to children receiving STD. Meta-
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analyses of past and ongoing clinical trials are necessary to confirm these findings before altering
clinical practice.
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Pediatric patients with critical illness experience high rates of hyperglycemia while
hospitalized in the intensive care unit. Almost 90% of children undergoing cardiac surgery
develop hyperglycemia in the post-operative period. 1-4 Previous observational studies
provide conflicting evidence about the association between hyperglycemia and morbidity
and mortality in these patients. 3, 5-7 Data from adult cardiac surgical populations 8
suggested the need for an experimental trial to determine whether post-operative tight
glycemic control (TGC) with insulin therapy provided benefit over standard blood glucose
management. We previously reported the results of the Safe Pediatric Euglycemia after
Cardiac Surgery (SPECS) trial 9 where we compared TGC to standard care (STD) in
patients from birth to 36 months undergoing cardiac surgery with cardiopulmonary bypass,
and showed that TGC did not reduce the incidence of post-operative healthcare-associated
infections or mortality.
Though we found no differences between the treatment and standard care groups in the
SPECS trial, it remains possible that heterogeneity of treatment effect exists across the study
population; both the effectiveness and safety of the treatment can vary between patients with
different risks for the primary outcome and treatment harm. 10 Therefore, we aimed to
investigate whether there were differential effects of TGC on outcomes in certain
identifiable subgroups within the SPECS trial cohort. We focused this analysis on subgroups
believed a priori to be at higher risk for infections and other morbidities. The results of this
exploratory analysis are meant to inform subsequent research on TGC in critically ill
children so that conflicting evidence and remaining knowledge gaps can be specifically
addressed in future experimental trials and meta-analyses.
Methods
The present study is a post-hoc analysis of the SPECS study database: the SPECS trial
methods, statistical analysis plan, and results have been published previously. 9, 11 The
SPECS trial (ClinicalTrials.gov number NCT00443599) was a two-center, randomized,
controlled trial that enrolled 980 children from birth to 36 months at the time of surgery with
cardiopulmonary bypass who received post-operative care in the cardiac intensive care unit
(CICU) at either Boston Children's Hospital or the University of Michigan C.S. Mott
Children's Hospital. Patients were randomized to receive either TGC (targeting
normoglycemia; 80 to 110 mg/dL [4.4 to 6.1 mmol/L]) or STD during their recovery in the
CICU. Insulin infusions were used to maintain blood glucose levels in the TGC group and
doses were titrated according to a proportional-integral-derivative algorithm, which is
modeled on beta cell physiology. 12, 13 Both treatment groups were monitored with
subcutaneous continuous glucose monitors to assist in glucose control and avoidance of
hypoglycemia.
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The primary outcome for the trial was incidence of 30-day healthcare-associated infections,
which included pneumonia, bloodstream, urinary tract, and surgical site infections, as
defined by Centers for Disease Control and Prevention (CDC), per 1,000 CICU days. 14
Secondary outcomes included mortality, cardiac index, duration of vasoactive support and
mechanical ventilation, and CICU length of stay. Cardiac index was determined on
postoperative day 2 in patients who were mechanically ventilated, sedated, and had a
superior vena cava or pulmonary artery catheter in situ. We calculated cardiac index by the
Fick principle using oxygen consumption (VO2) measured by indirect calorimetry,
hemoglobin concentration, and the difference between arterial and mixed venous oxygen
saturation, as previously validated. 15 In the overall cohort, there was no treatment effect
identified in any of the primary or secondary outcomes. 9
To compare infection rates of SPECS subjects to historical trends we compiled infection
data for children less than 3 years of age who were admitted to the Boston Children's
Hospital CICU after cardiopulmonary bypass surgery but who did not participate in SPECS.
All patients meeting these criteria between 1/1/2005 and 12/31/2012 were included.
Infections in non-study patients were defined according to the same CDC criteria used in
SPECS and were adjudicated by the same individuals.
The study was approved by the institutional review boards at both Boston Children's
Hospital and the University of Michigan CS Mott Children's Hospital. Parents and/or
guardians of the patients gave written informed consent.
Statistical analysis
We previously reported pre-specified, high-risk subgroup analyses for patients with a Risk
Adjustment in Congenital Heart Surgery (RACHS-1) category 16 of 3 or higher (or not
assignable), or a length of stay in the CICU of 3 days or longer; the latter analysis was based
on a post-randomization factor. 9 We subsequently performed several stratified post-hoc
analyses to determine whether TGC had a differential effect on infection incidence in seven
other specific subgroups of the patient cohort. Based on chance alone, we would expect that
0.35 tests out of 7 tests for interaction would be statistically significant at the P<0.05 level.
The variables used for stratification were those that identified certain subgroups at greater
risk of infection and other post-operative morbidities. Seven risk factors present prior to
protocol initiation were considered: 1) age at surgery (≤30 vs. >30 days), 2) previous cardiac
surgery, 3) chromosomal anomaly, 4) intraoperative glucocorticoid therapy, 5) non-biologic
surgical implant used for repair, 6) delayed sternal closure, and 7) first post-operative blood
glucose (≥110 vs. <110 mg/dL). Some of these variables – for example, surgical complexity
and delayed sternal closure – have been associated with increased risk of healthcare-
associated infection in prior analyses, 17- 19 whereas others (e.g., chromosomal anomalies
and age) have been known to be associated with mortality and morbidity generally, but not
specifically with infection.
Within a subgroup, the effect of tight glycemic control on infection was assessed with the
use of odds ratios and exact 95% confidence intervals derived from conditional logistic
regression. Potential differential effects of TGC on infection across subgroups were
analyzed with the use of exact logistic regression that included the interaction between
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treatment group and risk factor after including both as main effects. Given the observed
heterogeneity of treatment effect by age at surgery, we explored logistic regression models
that included the effects of treatment group, age subgroup, and their interaction, using
different age cutoffs. We then used maximum likelihood and a likelihood ratio test-based
confidence interval to select an optimal age cutoff. Using this optimal age cutoff we then
assessed the potential differential effects of TGC on other outcomes across age subgroups
using exact logistic regression for binary outcomes, exact Poisson regression for count
outcomes or rates, Cox proportional hazards regression for time-to-event outcomes, and
linear regression for continuous outcomes. To explore other potential predictors of infection,
multivariable stepwise logistic regression was used. Infections rates in non-study patients
≤60 days old were compared to rates in non-study patients >60 days old using exact Poisson
regression. All reported P values are two-sided. Statistical analyses were performed with the
use of SAS software, version 9.3. The reporting of results below follows the “Guidelines for
Reporting Subgroup Analysis”. 20
Results
All 980 subjects from the original SPECS trial were included in the analyses. Table 1
displays the proportion of subjects with any 30-day healthcare-associated infection and the
odds ratio (OR) for infection by treatment arm (TGC vs. STD) within each of the subgroups
and the results of the associated tests for interaction. Exact logistic regression analyses
demonstrated significant interactions between treatment group and both neonate (age ≤30
days, P=0.03) and intraoperative glucocorticoid use (P=0.03) on the risk of infection (Table
1). Though the point estimates suggested a possible harmful effect of TGC in neonates (age
≤30 days at surgery) and a possible benefit of TGC in patients who did not receive
intraoperative glucocorticoids, neither effect was statistically significant at the 0.05 level
(P=0.07 and P=0.09, respectively).
Given the observed heterogeneity of treatment effect by age at surgery, we next sought to
determine empirically an optimal age cutoff. We explored this by running logistic regression
models that included the main effects of treatment group and age subgroup and the
interaction term as covariates, where age subgroup was defined using different cutoffs from
30 days to 12 months (Figure 1). Plotting the log likelihood from these models versus age
cutoff demonstrated that an age cutoff of 59 days (95% confidence interval 55-71 days via
the likelihood ratio test) best discriminated two age subgroups with differential risk of
infection based on treatment arm. The difference in model characteristics was negligible
when comparing models using an age cutoff of ≤59 days vs. ≤60 days, so for subsequent
analyses and ease of reporting we defined the age subgroups as those ≤60 days or >60 days
at the time of surgery.
The comparison of the infection outcome between treatment groups within the empirically
derived age subgroups is shown in Table 2. The rate and incidence of healthcare-associated
infections in subjects ≤60 days of age were significantly increased among those in the TGC
group compared to the STD group (rate 13.5 vs. 3.7 infections/1,000 CICU days, P=0.01;
incidence 13% vs. 4%, P=0.02), while the rate and incidence of infections among those >60
days of age were significantly reduced in the TGC group compared to the STD group (rate
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5.0 vs. 14.1 infections/1,000 CICU days, P=0.02; incidence 2% vs. 5%, P=0.03). The
treatment group by age subgroup interactions were highly significant (P=0.001 for each).
These analyses did not appreciably change with adjustment for site. There was a differential
treatment group by age subgroup effect across the four CDC-defined infection types.
In light of the opposing effects of treatment on infection in the two age subgroups, ≤60 days
and 60 days to 3 years, we did not find any statistically significant differences in the baseline
characteristics between treatment groups across the age subgroups, as detailed in
Supplemental Table 1. Our analysis of the historical Boston Children's Hospital CICU
cohort demonstrated that younger patients had a significantly lower overall infection rate
compared to older patients (8.0 infections/1,000 CICU days in 1,061 patients ≤60 days of
age vs. 12.7 infections/1,000 CICU days in 2,035 patients >60 days; P<0.001).
Blood glucose management differed slightly across the two age subgroups with the
percentage of subjects receiving insulin being slightly higher in the younger subgroup (age
≤60 days: TGC 95% vs. STD 6%; age >60 days: TGC 89% vs. STD <1%; interaction
P=0.048) but was otherwise not distinguishable. Rates of any hypoglycemia (blood glucose
<60 mg/dL) were similarly (interaction P=0.84) elevated in the TGC arm compared with the
STD arm in both the younger cohort (TGC 35% vs. STD 18%) and the older cohort (TGC
13% vs. STD 7%). The overall time-weighted glucose average (TWGA) was significantly
different (P<0.001) between treatment groups in both age subgroups [age ≤60 days: TGC
median 107 (interquartile range 100-115) vs. STD 112 (104-125) mg/dL; age >60 days:
TGC 114 (106-122) vs. STD 124 (111-140) mg/dL]. Examination of daily TWGA revealed
that TWGA in the TGC group was significantly lower on days 1 and 2 compared to the STD
group for patients ≤60 days, while in the older cohort the TWGA difference between
treatment arms extended to 3 days, increasing the duration of exposure to treatment
differences from TGC within the >60 days subgroup (Figure 2).
Secondary study outcomes were largely similar between treatment groups across the age
subgroups with the exceptions of cardiac index and red blood cell transfusions, as shown in
Table 3. In the younger cohort (≤60 days) there was no benefit of TGC on cardiac index on
postoperative day 2 (TGC 0.9 vs. STD 1.3 L/min/m2; P=0.12), while in the older cohort
there appeared to be a 26% increase with TGC (TGC 2.4 vs. STD 1.9 L/min/m2; P=0.03).
The interaction between treatment group and age subgroup for this analysis was not
significant (P=0.15). Further, in all subjects potentially eligible for cardiac index
measurement (those intubated on post-operative day 2), there were no differences between
treatment groups in mortality, length of CICU or hospital stay, length of vasoactive support,
or transfusions in the >60 days subgroup.
There was an increased incidence of transfusion amongst those ≤60 days randomized to
TGC (TGC 76% vs. STD 63%; P=0.04), while there was no difference between treatment
groups in the >60 days subgroup. The frequency of blood glucose sampling in the overall
TGC cohort was greater than in the STD cohort (TGC mean 17 times per CICU day vs. STD
4 times per CICU day). The interaction between treatment group and age subgroup for this
analysis was not significant at the 0.05 level (P=0.058).
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To explore the potential effects of other factors present prior to protocol initiation on
infection, we performed multivariable stepwise logistic regression adjusting for treatment
group, age subgroup, and their interaction. Other factors significantly associated with
infection included previous cardiac surgery [OR (95% CI) 3.08 (1.41-6.72); P=0.003],
chromosomal anomaly [3.05 (1.39-6.51); P=0.005], and delayed sternal closure [4.32
(1.83-10.19); P<0.001]. Although intraoperative glucocorticoid use differed by age (71%
subjects ≤60 days received glucocorticoids vs. 45% subjects >60 days; P<0.001), further
adjustment for intraoperative glucocorticoid use did not appreciably affect these results.
Similarly, further adjustment for site did not appreciably affect the results.
Discussion
In this exploratory analysis of our study cohort from a large randomized controlled trial of
tight glycemic control we found differential response to the intervention among patients ≤60
days versus those >60 days of age at the time of surgery. Our analysis suggests that younger
patients had an increased rate of healthcare-associated infections with TGC compared to
STD while the older patients had a lower rate with TGC compared to STD. There is a
history of younger children having increased mortality with insulin therapy in the NIRTURE
trial. 21 The NIRTURE study was ongoing at the time of the design of our trial and was
subsequently halted early due to potential for harm in the treatment group. Other TGC trials
in children 22-24 have not reported analyses of the interaction of treatment group with age
subgroups.
To our knowledge, there are no other data suggesting a 60-day age cutoff for differential
response to TGC. It is conceivable that TGC confers benefits that have more relevance to
the older child whose maternally-acquired, antibody-mediated immunity has waned, 25, 26 as
opposed to the infant who also may be more susceptible to protocol-associated
hypoglycemia and anemia.27, 28 These theories will remain speculative, however, until
further data can be analyzed confirming the presence of a differential effect above and
below 60 days of age in other TGC trial populations.
Upon initial examination of our data, there appeared to be a low rate of infection in the
patients randomized to the STD arm in the younger age subgroup. These patients typically
have more complex surgery, higher rates of delayed sternal closure, greater exposure to
intravenous catheters, and longer CICU stays, and thus might be expected to have a higher
infection rate than older infants and children. In order to determine whether the low rate of
infection observed in STD subjects ≤60 days old was related to the study procedures used,
we evaluated historical data from non-study patients treated in the Boston Children's
Hospital CICU. These rates, assessed over the years 2005 to 2012 and previously
unpublished, showed similar trends to the rates seen in SPECS. We concluded that the
relationship between infection rates in younger (≤60 days) compared to older patients
observed in the STD arm of the SPECS trial was consistent with historical trends.
The striking interaction between treatment group and age subgroup on infection rates led us
to investigate other clinical outcomes to further explore the benefits of TGC in the older
patients. We observed that patients >60 days treated with TGC had significantly higher
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cardiac index on post-operative day 2 compared to those in the STD arm, though the
interaction between treatment group and age subgroup on this outcome was not statistically
significant. This analysis was limited to those in the Boston Children's Hospital CICU with a
central venous catheter in the superior vena caval circulation, and who remained intubated
on the second post-operative day, as the measurement of oxygen consumption was
conducted via the ventilator exhalation valve. Though it is a smaller subset of the overall
cohort (N=191), this group of patients, due to higher illness severity, may be most likely to
derive benefit from TGC if benefit exists. Both in vitro studies and prior clinical
reports 29-32 demonstrate the potential benefits to the myocardium of controlling blood
glucose with insulin infusion, specifically in mitigating the effects of ischemia-reperfusion
injury. Improved myocardial recovery should lead to other important outcome differences,
but we observed similar durations of mechanical ventilation, vasoactive support, and CICU
and hospital length of stay between treatment arms in the >60 days subgroup. However,
these outcomes were calculated for the entire >60 days subgroup, so it may be that only
those patients with greater post-operative organ dysfunction (e.g., those mechanically
ventilated greater than 48 hours) reap the benefits of TGC. Further analysis of past and
ongoing pediatric TGC clinical trials, focusing on patients with the greatest illness severity,
may elucidate the possible benefits of TGC to cardiopulmonary recovery.
Younger patients in the TGC arm also had a higher transfusion rate compared to the STD
arm, and there was a trend toward a significant interaction between treatment group and age
subgroup on transfusion (P=0.058). The increased transfusion rate in the TGC subjects in the
≤60 days cohort is likely a reflection of the increased frequency of blood glucose sampling
in the overall TGC cohort compared with STD. Given the smaller body mass and circulating
blood volume in the ≤60 days cohort, a similar volume of blood drawn would represent a
greater relative amount of blood loss, possibly leading to an increased transfusion rate. This
would explain why the same difference in number of blood draws was not associated with
increased transfusion rate in the older cohort. We attempted to mitigate this effect in the trial
design by using a blood conservation device as well as a bedside glucose meter that required
small amounts of blood. There are important limitations to the findings reported in this
manuscript. Most importantly, these are exploratory findings based on our initial observation
that statistically significant interactions existed between treatment group and age subgroup
on rate and incidence of infection. Although there is biologic plausibility for differential
immune function at 60 days of age, the age cutoff we report here has not been suggested
before in the critical care or TGC clinical literature. Some strengths of our analysis,
however, are that this secondary analysis showed a statistically significant treatment group
with age subgroup interaction on our primary outcome variable, the 95% confidence interval
for the optimal age cutoff was fairly tight (55-71 days), and the characteristics of our STD
cohort are consistent with a historical CICU population. We have conducted our analysis
and reported the findings in accordance with guidelines recommended by other authors for
subgroup analyses of randomized clinical trials. 20, 33 To remain consistent with these
recommendations, the findings herein should be interpreted conservatively. The results are
appropriately considered hypothesis-generating, rather than confirmatory. It will be crucial
to evaluate whether patients greater than 60 days of age demonstrate benefit from TGC in
analyses of recent and ongoing clinical trials in the context of a planned meta-analysis.
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However, based on the overall null finding in the trial, and the results of this analysis, we
would not recommend post-operative TGC for patients ≤60 days of age who undergo
cardiac surgery.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Exploring the age cutoff. Plot of the log likelihood from logistic regression models, which
included the main effects of treatment group and age subgroup (as defined using different
age cutoffs) and the interaction term as covariates, versus age cutoff. The maximum
likelihood estimate (MLE) is 59 days (confidence interval 55-71 days).
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Figure 2.
Time-weighted Blood Glucose Average by Day, According to Treatment Group and Age
Subgroup. The panels show time-weighted blood glucose averages (TWBA) calculated from
all blood glucose samples on the day of post-operative admission to the cardiac intensive
care unit (CICU) (day 1) and the subsequent two days (7 a.m. to 6:59 a.m.). Panel A shows
the TWGA by day for subjects ≤60 days old at the time of surgery, while Panel B shows the
TWGA by day for subjects >60 days old. The points represent the medians, while the error
bars extend to the 25th and 75th percentiles. NS denotes not significant.
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Table 1
Effect of Tight Glycemic Control on Healthcare-Associated Infections in Subgroups
Subgroup Patients, No. Patients with Infectiona, No.
(%)
Odds Ratio (Exact 95%
CI)
Exact P Value for
Interactionb
TGC STD TGC STD
Overall 490 490 24 (5) 24 (5) 1.00 (0.54-1.87) -
RACHS-1 categoryc 0.09
≥3 or Not assignable 263 250 21 (8) 15 (6) 1.36 (0.65-2.91)
1-2 227 240 3 (1) 9 (4) 0.34 (0.06-1.40)
Age at surgery 0.03
≤30 days 99 99 12 (12) 4 (4) 2.95 (0.85-13.05)
>30 days 391 400 12 (3) 20 (5) 0.60 (0.26-1.31)
Previous cardiac surgery 0.37
Yes 119 118 7 (6) 10 (8) 0.68 (0.21-2.05)
No 371 372 17 (5) 14 (4) 1.23 (0.56-2.74)
Chromosomal anomaly 0.33
Yes 94 98 5 (5) 9 (9) 0.56 (0.14-1.94)
No 396 392 19 (5) 15 (4) 1.27 (0.60-2.72)
Intraoperative glucocorticoid therapy 0.03
Yes 255 247 19 (7) 11 (4) 1.73 (0.76-4.11)
No 235 243 5 (2) 13 (5) 0.39 (0.11-1.18)
Implant left during surgery 1.0
Yes 317 320 18 (6) 19 (6) 0.95 (0.46-1.96)
No 173 170 6 (3) 5 (3) 1.19 (0.30-5.01)
Delayed sternal closure 0.53
Yes 63 58 10 (16) 7 (12) 1.37 (0.43-4.59)
No 427 432 14 (3) 17 (4) 0.83 (0.37-1.81)
First post-operative blood glucose 1.0
>110 mg/dL 352 356 19 (5) 19 (5) 1.01 (0.50-2.06)
≤110 mg/dL 138 134 5 (4) 5 (4) 0.97 (0.22-4.32)
TGC denotes Tight Glycemic Control, STD Standard Care, CI confidence interval, RACHS-1 Risk Adjustment in Congenital Heart Surgery, and
CICU cardiac intensive care unit.
a
Healthcare-associated infections include pneumonia, bloodstream, and urinary tract infections, which were tracked for up to 30 days in the CICU
or until 48 hours after discharge from the CICU, and surgical site infections, which were tracked for 30 days after the index procedure. For patients
who remained in the CICU for more than 30 days, the number of patient-days in the CICU was considered to be 30.
b
The P values for the interaction between treatment group and risk factor were calculated from logistic regression models including the main
effects and interaction term as covariates.
c
The scale for RACHS-1 categories ranges from 1 to 6, with higher categories indicating greater risk.
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Table 2
Healthcare-Associated Infections, According to Treatment Group and Age Subgroup
Infections Outcome Age ≤60 Days Relative Risk or
Odds Ratio
(Exact 95% CI)
Age >60 Days Relative Risk
or Odds Ratio
(Exact 95%)
Exact P
Value for
Interactiona
TGC (n=128) STD (n=113) TGC (n=362) STD (n=377)
Infectionsb, no. of
patients (%)
    Any infections
        Yes 16 (13) 4 (4) 3.87 (1.20-16.43) 8 (2) 20 (5) 0.40 (0.15-0.97) 0.001
        No 112 (88) 109 (96) 354 (98) 357 (95)
    No. of infections
        0 112 (88) 109 (96) 354 (98) 357 (95) 0.001
        1 16 (13) 4 (4) 8 (2) 18 (5)
        2 0 0 0 2 (<1)
30-day rate of
healthcare-
associated
infections, no. of
infections/1,000
days in CICU
13.5 3.7 3.68 (1.19-15.11) 5.0 14.1 0.39 (0.15-0.92) 0.001
Type of infection,
no.
    Pneumonia 1 0 2 3
    Bloodstream 3 0 0 4
    Urinary tract 1 0 1 6
    Surgical site 11 4 5 9
TGC denotes Tight Glycemic Control, STD Standard Care, CI confidence interval, and CICU cardiac intensive care unit.
a
The P values for the interaction between treatment group and age subgroup were calculated from logistic regression models for the proportion of
subjects with any infection or exact Poisson regression models for the number of infections and 30-day infection rate. These models included the
main effects and interaction term as covariates.
b
Healthcare-associated infections include pneumonia, bloodstream, and urinary tract infections, which were tracked for up to 30 days in the CICU
or until 48 hours after discharge from the CICU, and surgical site infections, which were tracked for 30 days after the index procedure. For patients
who remained in the CICU for more than 30 days, the number of patient-days in the CICU was considered to be 30.
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Table 3
Study Outcomes, According to Treatment Group and Age Subgroup
Outcome Age ≤60 Days Age >60 Days P Value for Interactiona
TGC (n=128) STD (n=113) TGC (n=362) STD (n=377)
30-day mortality, no./total no. (%)b 2/128 (2) 5/112 (4) 3/360 (<1) 1/372 (<1) 0.22
Length of stay in the CICU, daysc 0.46
    Median 6.7 6.5 2.1 2.1
    IQR 4.3-12.0 4.0-12.8 1.7-4.8 1.6-4.6
Length of stay in the hospital, daysc 0.42
    Median 14.5 15 7 6
    IQR 9-26.5 9-29 5-11 5-10
Mechanical ventilation, daysc 0.50
    Median 5 5 2 2
    IQR 4-8 3-10 1-3 1-3
Cardiac index on day 2, L/min/m2,d 0.15
    Median 0.9 1.3 2.4 1.9
    IQR 0.7-1.5 1.0-1.9 1.8-3.2 1.5-2.7
Vasoactive support, days 0.99
    Median 5 5 2 2
    IQR 3-8.5 3-9 0-3 0-3
Red-cell transfusion, no. (%) 97 (76) 71 (63) 173 (48) 181 (48) 0.058
TGC denotes Tight Glycemic Control, STD Standard Care, CICU cardiac intensive care unit, and IQR interquartile range.
a
The P values for the interaction between treatment group and age subgroup were calculated from logistic regression models for binary outcomes,
Cox proportional hazards regression models for time-to-event outcomes, or a linear regression model for cardiac index. These models included the
main effects and interaction term as covariates.
b
Eight patients were lost to follow-up between hospital discharge and study day 30.
c
The duration of the stay in the CICU, the stay in the hospital, and mechanical ventilation were considered to be 30 days for patients with duration
of more than 30 days and for the 11 patients who died in the CICU by the 30th day.
d
The cardiac index on day 2 was measured in 191 patients at Boston Children's Hospital.
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